

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

02/20
Licensee

318651

<p>1. West Branch Regional Medical Center</p> <p>2. 2463 South M-30 West Branch, MI 48661</p>	<p>In accordance with letter dated November 10, 2009,</p> <p>3. License number 21-18892-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date November 30, 2010</p> <hr/> <p>5. Docket No. 030-17321 Reference No.</p>
---	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed 1 curie of iodine-133)
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed sources (Best Medical International, Inc. Model 2301)	D. 2 curies

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
 - D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

CONDITIONS

- 10. Location of Use: 2463 S. M-30, West Branch, Michigan; and West Branch Regional Cancer Center, 2431 South M-30, West Branch, Michigan (limited to 10 CFR 35.100 and 35.200 materials; except generators and xenon-133).
- 11. **A. Radiation Safety Officer: Matthew Waack, M.D.**
- B. Radiation Safety Officer for 10 CFR 35.400 material only is Jacek Wierzbicki, Ph.D.

License Number
21-18892-01

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

Docket or Reference Number
030-17321

Amendment No. 28

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Ram K. Gadam, M.D. 10 CFR 35.100, 35.200, 35.300 and 35.400.

George F. Ascherl, M.D. 10 CFR 35.100, 35.200 and 35.300.

Joseph E. Talbot, M.D. 10 CFR 35.100, 35.200 and 35.300.

Scott E. Cheney, M.D. 10 CFR 35.100, and 35.200..

Sanjay J. Talatim, M.D. 10 CFR 35.100, and 35.200.

C. E. Mueller, M.D. 10 CFR 35.100, 35.200 and 35.300.

Robert B. Saltzman, M.D. 10 CFR 35.100, 35.200 and 35.300.

Mark R. Pennington, M.D. 10 CFR 35.100, 35.200 and 35.300.

Rey Alberto H. Franco, M.D. 10 CFR 35.200

Matthew Waack, M.D. 10 CFR 35.100, 35.200 and 35.300.

Richard P. Heuschele, M.D. 10 CFR 35.100 and 35.200

Mark R. Ludka, M.D. 10 CFR 35.100, 35.200, and 35.300.

Khurshid Ahmad, M.D. 10 CFR 35.300 and 35.400

Michael Cappelli, M.D. 10 CFR 35.400

Young Kim, M.D. 10 CFR 35.300 and 35.400

Ihn Han, M.D., Ph.D. 10 CFR 35.300 and 35.400

Kristin M. Nelsen, M.D. 10 CFR 35.100, and 35.200.

Shahzad Sadiz, M.D. 10 CFR 35.100, 35.200 and 35.300.

License Number
21-18892-01

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

Docket or Reference Number
030-17321

Amendment No. 28

Sultan Bhimani, M.D.	10 CFR 35.100, and 35.200.
Rita Ratani, M.D.	10 CFR 35.100, and 35.200.
Harvey Yee, M.D.	10 CFR 35.100, 35.200 and 35.300.
George Ascherl, M.D.	10 CFR 35.100, 35.200 and 35.300.
Chirdeep Bhutani, M.D.	10 CFR 35.100, 35.200 and 35.300.
Sambasiva Kottamasu, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to sodium iodide-131 in quantities less than or equal to 33 millicuries).

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated June 28, 2000 (with attachments except Item 12.1 "Radiopharmaceutical Quality Management Program"); and
- B. Letters dated August 9, 2000, and January 30, 2006.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date DEC 04 2009

By James R. Mullauer
James R. Mullauer, M.H.S.
Materials Licensing Branch
Region III